{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:20:26Z","timestamp":1786544426792,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22H03000"],"award-info":[{"award-number":["JP22H03000"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22H00494"],"award-info":[{"award-number":["JP22H00494"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21H05694"],"award-info":[{"award-number":["JP21H05694"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22H02944"],"award-info":[{"award-number":["JP22H02944"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22dk0207065"],"award-info":[{"award-number":["JP22dk0207065"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21wm0425010"],"award-info":[{"award-number":["JP21wm0425010"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22H02944"],"award-info":[{"award-number":["JP22H02944"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001695","name":"Japan Science and Technology Corporation","doi-asserted-by":"publisher","award":["JPMJSP2138"],"award-info":[{"award-number":["JPMJSP2138"]}],"id":[{"id":"10.13039\/501100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001695","name":"Japan Science and Technology Corporation","doi-asserted-by":"publisher","award":["JPMJSP2138"],"award-info":[{"award-number":["JPMJSP2138"]}],"id":[{"id":"10.13039\/501100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008667","name":"SENSHIN Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016289","name":"Taiju Life Social Welfare Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Collaborative Research Program of Institute for Protein Research, Osaka University","award":["ICR-22-03"],"award-info":[{"award-number":["ICR-22-03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Schizophrenia is a psychiatric disorder that affects around 1% of the population in widespread populations, with severe cases leading to long-term hospitalization and necessitation of lifelong treatment. Recent studies on schizophrenia have highlighted the involvement of inflammatory and immunoregulatory mechanisms with the onset of symptoms, and the usage of anti-inflammatory treatments are being tested against periods of rapid psychosis. In the central nervous system, microglia are the innate immune population which are activated in response to a wide range of physical and psychological stress factors and produce proinflammatory mediators such as cytokines. Microglial activation and neuroinflammation has been associated to numerous psychiatric disorders including schizophrenia, especially during psychotic episodes. Thus, novel treatments which dampen microglial activation may be of great relevance in the treatment of psychiatric disorders. Fingolimod (FTY720) is a drug used as an immunosuppressive treatment to multiple sclerosis. Recent clinical trials have focused on FTY720 as a treatment for the behavioral symptoms in schizophrenia. However, the mechanisms of Fingolimod in treating the symptoms of schizophrenia are not clear. In this study we use a recently developed neuroinflammatory psychosis model in mice: cuprizone short-term exposure, to investigate the effects of FTY720 administration. FTY720 administration was able to completely alleviate methamphetamine hypersensitivity caused by cuprizone exposure. Moreover, administration of FTY720 improved multiple measures of neuroinflammation (microglial activation, cytokine production, and leucocyte infiltration). In conclusion, our results highlight the future use of FTY720 as a direct anti-inflammatory treatment against microglial activation and psychosis.<\/jats:p>","DOI":"10.1186\/s13041-023-01047-5","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T12:01:51Z","timestamp":1689163311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice"],"prefix":"10.1186","volume":"16","author":[{"given":"Siyao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6952-7749","authenticated-orcid":false,"given":"Koki","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohgidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro A.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Hikida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"issue":"2\u20133","key":"1047_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.schres.2009.09.022","volume":"115","author":"S Galderisi","year":"2009","unstructured":"Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, Rybakowski JK, Libiger J, Dollfus S, L\u00f3pez-Ibor JJ, Peuskens J, Hranov LG, Fleischhacker WW, EUFEST group. Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. Schizophr Res. 2009;115(2\u20133):104\u201314.","journal-title":"Schizophr Res"},{"issue":"5","key":"1047_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11920-996-0038-7","volume":"3","author":"PD Harvey","year":"2001","unstructured":"Harvey PD, Bowie CR, Friedman JI. Cognition in schizophrenia. Curr Psychiatry Rep. 2001;3(5):423\u20138.","journal-title":"Curr Psychiatry Rep"},{"issue":"12","key":"1047_CR3","first-page":"1821","volume":"75","author":"SH Schultz","year":"2007","unstructured":"Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician. 2007;75(12):1821\u20139.","journal-title":"Am Fam Physician"},{"issue":"2","key":"1047_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-an overview. JAMA Psychiat. 2020;77(2):201.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"1047_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0269881114563634","volume":"29","author":"O Howes","year":"2015","unstructured":"Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29(2):97\u2013115.","journal-title":"J Psychopharmacol"},{"key":"1047_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.bbi.2020.04.039","volume":"88","author":"N \u00c7akici","year":"2020","unstructured":"\u00c7akici N, Sutterland AL, Penninx BWJH, Dalm VA, de Haan L, van Beveren NJM. Altered peripheral blood compounds in drug-na\u00efve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. Brain Behav Immun. 2020;88:547\u201358.","journal-title":"Brain Behav Immun"},{"issue":"8","key":"1047_CR7","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/sj.npp.1300217","volume":"28","author":"DL Garver","year":"2003","unstructured":"Garver DL, Tamas RL, Holcomb JA. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology. 2003;28(8):1515\u201320.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"1047_CR8","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s11682-020-00375-7","volume":"15","author":"MM Francis","year":"2021","unstructured":"Francis MM, Hummer TA, Liffick E, Vohs JL, Mehdiyoun NF, Visco AC, Yang Z, et al. Effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, on white matter microstructure, cognition and symptoms in schizophrenia. Brain Imaging Behav. 2021;15(4):1802\u201314.","journal-title":"Brain Imaging Behav"},{"issue":"14","key":"1047_CR9","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1017\/S0033291719001995","volume":"49","author":"N \u00c7akici","year":"2019","unstructured":"\u00c7akici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019;49(14):2307\u201319.","journal-title":"Psychol Med"},{"issue":"10","key":"1047_CR10","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","volume":"21","author":"S Hickman","year":"2018","unstructured":"Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21(10):1359\u201369.","journal-title":"Nat Neurosci"},{"key":"1047_CR11","first-page":"35","volume":"26","author":"M Colonna","year":"2017","unstructured":"Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;26:35.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"1047_CR12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/nn1997","volume":"10","author":"UK Hanisch","year":"2007","unstructured":"Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10(11):1387\u201394.","journal-title":"Nat Neurosci"},{"key":"1047_CR13","first-page":"42","volume":"5","author":"A Monji","year":"2013","unstructured":"Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M, Yamauchi Y, Yamada S, Kanba S. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;5:42.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"1047_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1440-1819.2009.01945.x","volume":"63","author":"A Monji","year":"2009","unstructured":"Monji A, Kato T, Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009;63(3):257\u201365.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"1047_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/00207454.2013.833510","volume":"124","author":"Z Cai","year":"2014","unstructured":"Cai Z, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer\u2019s disease. Int J Neurosci. 2014;124(5):307\u201321.","journal-title":"Int J Neurosci"},{"key":"1047_CR16","first-page":"302","volume":"27","author":"V Sanchez-Guajardo","year":"2015","unstructured":"Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. The relation between \u03b1-synuclein and microglia in Parkinson\u2019s disease: Recent developments. Neuroscience. 2015;27:302.","journal-title":"Neuroscience"},{"issue":"1","key":"1047_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40478-017-0424-x","volume":"5","author":"J Cooper-Knock","year":"2017","unstructured":"Cooper-Knock J, Green C, Altschuler G, Wei W, Bury JJ, Heath PR, Wyles M, et al. A data-driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2017;5(1):23.","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"1047_CR18","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/awx113","volume":"140","author":"T Zrzavy","year":"2017","unstructured":"Zrzavy T, Hametner S, Wimmer I, Butovsky O, Weiner HL, Lassmann H. Loss of \u201chomeostatic\u201d microglia and patterns of their activation in active multiple sclerosis. Brain. 2017;140(7):1900\u201313.","journal-title":"Brain"},{"issue":"9","key":"1047_CR19","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/0269881112444941","volume":"26","author":"IB Chaudhry","year":"2012","unstructured":"Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, Dursun S, Dunn G, Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26(9):1185\u201393.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"1047_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","volume":"71","author":"Y Levkovitz","year":"2010","unstructured":"Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71(2):138\u201349.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1047_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/WNF.0b013e3181593d45","volume":"31","author":"T Miyaoka","year":"2008","unstructured":"Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol. 2008;31(5):287\u201392.","journal-title":"Clin Neuropharmacol"},{"key":"1047_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","volume":"185","author":"A Huwiler","year":"2018","unstructured":"Huwiler A, Zangemeister-Wittke U. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives. Pharmacol Ther. 2018;185:34\u201349.","journal-title":"Pharmacol Ther"},{"issue":"1\u20132","key":"1047_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","volume":"328","author":"A Groves","year":"2013","unstructured":"Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013;328(1\u20132):9\u201318.","journal-title":"J Neurol Sci"},{"issue":"2","key":"1047_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91\u2013101.","journal-title":"Clin Neuropharmacol"},{"issue":"13","key":"1047_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.807639","volume":"16","author":"S Pournajaf","year":"2022","unstructured":"Pournajaf S, Dargahi L, Javan M, Pourgholami MH. Molecular pharmacology and novel potential therapeutic applications of fingolimod. Front Pharmacol. 2022;16(13): 807639.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1047_CR26","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.3390\/ijms20092257","volume":"20","author":"E Pandur","year":"2019","unstructured":"Pandur E, Pap R, Varga E, J\u00e1nosa G, Komoly S, F\u00f3rizs J, Sipos K. Relationship of iron metabolism and short-term cuprizone treatment of C57BL\/6 mice. Int J Mol Sci. 2019;20(9):2257.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"1047_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fnana.2020.00030","volume":"9","author":"M Luo","year":"2020","unstructured":"Luo M, Deng M, Yu Z, Zhang Y, Xu S, Hu S, Xu H. Differential susceptibility and vulnerability of brain cells in C57BL\/6 mouse to mitochondrial dysfunction induced by short-term cuprizone exposure. Front Neuroanat. 2020;9(14):30.","journal-title":"Front Neuroanat"},{"key":"1047_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neures.2016.01.006","volume":"107","author":"MA Kondo","year":"2016","unstructured":"Kondo MA, Fukudome D, Smith DR, Gallagher M, Kamiya A, Sawa A. Dimensional assessment of behavioral changes in the cuprizone short-term exposure model for psychosis. Neurosci Res. 2016;107:70\u20134.","journal-title":"Neurosci Res"},{"key":"1047_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.nbd.2013.07.003","volume":"59","author":"T Tezuka","year":"2013","unstructured":"Tezuka T, Tamura M, Kondo MA, Sakaue M, Okada K, Takemoto K, Fukunari A, et al. Cuprizone short-term exposure: astrocytic IL-6 activation and behavioral changes relevant to psychosis. Neurobiol Dis. 2013;59:63\u20138.","journal-title":"Neurobiol Dis"},{"issue":"9","key":"1047_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3389\/fpsyt.2018.00491","volume":"10","author":"TA Wearne","year":"2018","unstructured":"Wearne TA, Cornish JL. A comparison of methamphetamine-induced psychosis and schizophrenia: a review of positive, negative, and cognitive symptomatology. Front Psychiatry. 2018;10(9):491.","journal-title":"Front Psychiatry"},{"issue":"2","key":"1047_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jpsychires.2006.10.013","volume":"42","author":"J Steiner","year":"2008","unstructured":"Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42(2):151\u20137.","journal-title":"J Psychiatr Res"},{"issue":"9","key":"1047_CR32","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.biopsych.2008.04.025","volume":"64","author":"BN van Berckel","year":"2008","unstructured":"van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, Luurtsema G, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64(9):820\u20132.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"1047_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fpsyt.2017.00083","volume":"23","author":"S Najjar","year":"2017","unstructured":"Najjar S, Pahlajani S, De Sanctis V, Stern JNH, Najjar A, Chong D. Neurovascular unit dysfunction and blood-brain barrier hyperpermeability contribute to schizophrenia neurobiology: a theoretical integration of clinical and experimental evidence. Front Psychiatry. 2017;23(8):83.","journal-title":"Front Psychiatry"},{"issue":"3","key":"1047_CR34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.neuron.2018.06.035","volume":"99","author":"X Nie","year":"2018","unstructured":"Nie X, Kitaoka S, Tanaka K, Segi-Nishida E, Imoto Y, Ogawa A, Nakano F, Tomohiro A, Nakayama K, Taniguchi M, Mimori-Kiyosue Y, Kakizuka A, Narumiya S, Furuyashiki T. The innate immune receptors TLR2\/4 mediate repeated social defeat stress-induced social avoidance through prefrontal microglial activation. Neuron. 2018;99(3):464-479.e7.","journal-title":"Neuron"},{"issue":"1","key":"1047_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pneurobio.2010.09.004","volume":"93","author":"N Takahashi","year":"2011","unstructured":"Takahashi N, Sakurai T, Davis KL, Buxbaum JD. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog Neurobiol. 2011;93(1):13\u201324.","journal-title":"Prog Neurobiol"},{"issue":"9386","key":"1047_CR36","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0140-6736(03)14289-4","volume":"362","author":"D Tkachev","year":"2003","unstructured":"Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362(9386):798\u2013805.","journal-title":"Lancet"},{"key":"1047_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.brainresbull.2019.08.014","volume":"153","author":"M Hashemian","year":"2019","unstructured":"Hashemian M, Ghasemi-Kasman M, Parsian H, Sadeghi F. Fingolimod (FTY720) improves the functional recovery and myelin preservation of the optic pathway in focal demyelination model of rat optic chiasm. Brain Res Bull. 2019;153:109\u201321.","journal-title":"Brain Res Bull"},{"issue":"2","key":"1047_CR38","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1750-3639.2008.00182.x","volume":"19","author":"CA Foster","year":"2009","unstructured":"Foster CA, Mechtcheriakova D, Storch MK, Balatoni B, Howard LM, Bornancin F, Wlachos A, et al. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 2009;19(2):254\u201366.","journal-title":"Brain Pathol"},{"key":"1047_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb05178.x","volume":"914","author":"K Yui","year":"2000","unstructured":"Yui K, Ikemoto S, Ishiguro T, Goto K. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Ann N Y Acad Sci. 2000;914:1\u201312.","journal-title":"Ann N Y Acad Sci"},{"issue":"50","key":"1047_CR40","doi-asserted-by":"publisher","first-page":"11449","DOI":"10.1523\/JNEUROSCI.3597-04.2004","volume":"24","author":"KA Mark","year":"2004","unstructured":"Mark KA, Soghomonian JJ, Yamamoto BK. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci. 2004;24(50):11449\u201356.","journal-title":"J Neurosci"},{"issue":"12","key":"1047_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.644294","volume":"19","author":"A Mancini","year":"2021","unstructured":"Mancini A, Ghiglieri V, Parnetti L, Calabresi P, Di Filippo M. Neuro-immune cross-talk in the striatum: from basal ganglia physiology to circuit dysfunction. Front Immunol. 2021;19(12): 644294.","journal-title":"Front Immunol"},{"issue":"26","key":"1047_CR42","doi-asserted-by":"publisher","first-page":"6028","DOI":"10.1523\/JNEUROSCI.0713-04.2004","volume":"24","author":"PM Thompson","year":"2004","unstructured":"Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY, Toga AW, Ling W, London ED. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci. 2004;24(26):6028\u201336.","journal-title":"J Neurosci"},{"issue":"2","key":"1047_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1460-9568.2009.07059.x","volume":"31","author":"J Gon\u00e7alves","year":"2010","unstructured":"Gon\u00e7alves J, Baptista S, Martins T, Milhazes N, Borges F, Ribeiro CF, Malva JO, Silva AP. Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin. Eur J Neurosci. 2010;31(2):315\u201326.","journal-title":"Eur J Neurosci"},{"issue":"4","key":"1047_CR44","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1476-5381.2011.01579.x","volume":"165","author":"S Rossi","year":"2012","unstructured":"Rossi S, Lo Giudice T, De Chiara V, Musella A, Studer V, Motta C, Bernardi G, Martino G, Furlan R, Martorana A, Centonze D. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. Br J Pharmacol. 2012;165(4):861\u20139.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1047_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40268-020-00316-1","volume":"20","author":"P Bascu\u00f1ana","year":"2020","unstructured":"Bascu\u00f1ana P, M\u00f6hle L, Brackhan M, Pahnke J. Fingolimod as a treatment in neurologic disorders beyond multiple sclerosis. Drugs R D. 2020;20(3):197\u2013207.","journal-title":"Drugs R D"},{"issue":"6","key":"1047_CR46","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00401-009-0591-3","volume":"118","author":"M Kipp","year":"2009","unstructured":"Kipp M, Clarner T, Dang J, Copray S, Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol. 2009;118(6):723\u201336.","journal-title":"Acta Neuropathol"},{"issue":"7744","key":"1047_CR47","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41586-019-0924-x","volume":"566","author":"T Masuda","year":"2019","unstructured":"Masuda T, Sankowski R, Staszewski O, B\u00f6ttcher C, Amann L, Sagar, Scheiwe C, Nessler S, Kunz P, van Loo G, Coenen VA, Reinacher PC, Michel A, Sure U, Gold R, Gr\u00fcn D, Priller J, Stadelmann C, Prinz M. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature. 2019;566(7744):388\u201392.","journal-title":"Nature"},{"key":"1047_CR48","first-page":"48","volume":"3","author":"KS Na","year":"2014","unstructured":"Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;3:48.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1047_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/369693","volume":"2013","author":"M Hiroi","year":"2013","unstructured":"Hiroi M, Sakaeda Y, Yamaguchi H, Ohmori Y. Anti-inflammatory cytokine interleukin-4 inhibits inducible nitric oxide synthase gene expression in the mouse macrophage cell line RAW264.7 through the repression of octamer-dependent transcription. Mediators Inflamm. 2013;2013: 369693.","journal-title":"Mediators Inflamm"},{"issue":"5","key":"1047_CR50","first-page":"253","volume":"27","author":"P Chatterjee","year":"2014","unstructured":"Chatterjee P, Chiasson VL, Bounds KR, Mitchell BM. Regulation of the anti-inflammatory cytokines interleukin-4 and interleukin-10 during pregnancy. Front Immunol. 2014;27(5):253.","journal-title":"Front Immunol"},{"issue":"8","key":"1047_CR51","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.arcmed.2014.11.013","volume":"45","author":"GG Ortiz","year":"2014","unstructured":"Ortiz GG, Pacheco-Mois\u00e9s FP, Mac\u00edas-Islas M\u00c1, Flores Alvarado LJ, Mireles-Ram\u00edrez MA, Gonz\u00e1lez-Renovato ED, Hern\u00e1ndez-Navarro VE, et al. Role of the blood-brain barrier in multiple sclerosis. Arch Med Res. 2014;45(8):687\u201397.","journal-title":"Arch Med Res"},{"issue":"3","key":"1047_CR52","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s11481-019-09843-4","volume":"14","author":"S Yao","year":"2019","unstructured":"Yao S, Li L, Sun X, Hua J, Zhang K, Hao L, Liu L, Shi D, Zhou H. FTY720 inhibits MPP+-induced microglial activation by affecting NLRP3 inflammasome activation. J Neuroimmune Pharmacol. 2019;14(3):478\u201392.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"1","key":"1047_CR53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/JLB.3A0717-287R","volume":"103","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Shi D, Cao K, Wu F, Zhu X, Wen S, You Q, Zhang K, Liu L, Zhou H. Fingolimod targets cerebral endothelial activation to block leukocyte recruitment in the central nervous system. J Leukoc Biol. 2018;103(1):107\u201318.","journal-title":"J Leukoc Biol"},{"issue":"1\u20132","key":"1047_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jns.2008.06.031","volume":"274","author":"VE Miron","year":"2008","unstructured":"Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci. 2008;274(1\u20132):13\u20137.","journal-title":"J Neurol Sci"},{"issue":"8","key":"1047_CR55","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1073\/pnas.1615413114","volume":"114","author":"V Rothhammer","year":"2017","unstructured":"Rothhammer V, Kenison JE, Tjon E, Takenaka MC, de Lima KA, Borucki DM, Chao CC, Wilz A, Blain M, Healy L, Antel J, Quintana FJ. Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation. Proc Natl Acad Sci U S A. 2017;114(8):2012\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1047_CR56","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1038\/s41380-019-0509-y","volume":"25","author":"S Cetin-Karayumak","year":"2020","unstructured":"Cetin-Karayumak S, Di Biase MA, Chunga N, Reid B, Somes N, Lyall AE, Kelly S, et al. White matter abnormalities across the lifespan of schizophrenia: a harmonized multi-site diffusion MRI study. Mol Psychiatry. 2020;25(12):3208\u201319.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"1047_CR57","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201810248","volume":"11","author":"S Voet","year":"2019","unstructured":"Voet S, Srinivasan S, Lamkanfi M, van Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med. 2019;11(6): e10248.","journal-title":"EMBO Mol Med"},{"key":"1047_CR58","first-page":"1","volume":"6","author":"G Ozdamar Unal","year":"2022","unstructured":"Ozdamar Unal G, Hekimler Ozturk K, Inci HE. Increased NLRP3 inflammasome expression in peripheral blood mononuclear cells of patients with schizophrenia: a case-control study. Int J Psychiatry Clin Pract. 2022;6:1\u20137.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"1","key":"1047_CR59","doi-asserted-by":"publisher","first-page":"11882","DOI":"10.1038\/s41598-017-11506-4","volume":"7","author":"M Ohgidani","year":"2017","unstructured":"Ohgidani M, Kato TA, Hosoi M, Tsuda M, Hayakawa K, Hayaki C, Iwaki R, Sagata N, Hashimoto R, Inoue K, Sudo N, Kanba S. Fibromyalgia and microglial TNF-\u03b1: translational research using human blood induced microglia-like cells. Sci Rep. 2017;7(1):11882.","journal-title":"Sci Rep"},{"key":"1047_CR60","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3389\/fncel.2015.00184","volume":"9","author":"M Ohgidani","year":"2015","unstructured":"Ohgidani M, Kato TA, Kanba S. Introducing directly induced microglia-like (iMG) cells from fresh human monocytes: a novel translational research tool for psychiatric disorders. Front Cell Neurosci. 2015;9:184.","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"1047_CR61","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1038\/srep04957","volume":"14","author":"M Ohgidani","year":"2014","unstructured":"Ohgidani M, Kato TA, Setoyama D, Sagata N, Hashimoto R, Shigenobu K, Yoshida T, Hayakawa K, Shimokawa N, Miura D, Utsumi H, Kanba S. Direct induction of ramified microglia-like cells from human monocytes: dynamic microglial dysfunction in Nasu-Hakola disease. Sci Rep. 2014;14(4):4957.","journal-title":"Sci Rep"},{"issue":"1","key":"1047_CR62","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13024-022-00538-8","volume":"17","author":"M Zirngibl","year":"2022","unstructured":"Zirngibl M, Assinck P, Sizov A, Caprariello AV, Plemel JR. Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination. Mol Neurodegener. 2022;17(1):34.","journal-title":"Mol Neurodegener"},{"key":"1047_CR63","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;4:575\u201390.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1047_CR64","doi-asserted-by":"publisher","first-page":"13632","DOI":"10.1073\/pnas.2234031100","volume":"100","author":"CT Ekdahl","year":"2003","unstructured":"Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA. 2003;100:13632\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1047_CR65","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","volume":"30","author":"SF Hunter","year":"2016","unstructured":"Hunter SF, Bowen JD, Reder AT. The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis. CNS Drugs. 2016;30(2):135\u201347.","journal-title":"CNS Drugs"},{"issue":"6","key":"1047_CR66","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/bph.12012","volume":"168","author":"X Qin","year":"2013","unstructured":"Qin X, Yue Z, Sun B, Yang W, Xie J, Ni E, Feng Y, Mahmood R, Zhang Y, Yue L. Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels. Br J Pharmacol. 2013;168(6):1294\u2013312.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"1047_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258364","volume":"16","author":"K Sakurai","year":"2021","unstructured":"Sakurai K, Itou T, Morita M, Kasahara E, Moriyama T, Macpherson T, Ozawa T, Miyamoto Y, Yoneda Y, Sekiyama A, Oka M, Hikida T. Effects of importin \u03b11\/KPNA1 deletion and adolescent social isolation stress on psychiatric disorder-associated behaviors in mice. PLoS ONE. 2021;16(11): e0258364.","journal-title":"PLoS ONE"},{"issue":"16","key":"1047_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.905991","volume":"30","author":"Y Aomine","year":"2022","unstructured":"Aomine Y, Sakurai K, Macpherson T, Ozawa T, Miyamoto Y, Yoneda Y, Oka M, Hikida T. Importin \u03b13 (KPNA3) deficiency augments effortful reward-seeking behavior in mice. Front Neurosci. 2022;30(16): 905991.","journal-title":"Front Neurosci"},{"issue":"6","key":"1047_CR69","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/mp.2013.155","volume":"19","author":"T Kreisel","year":"2014","unstructured":"Kreisel T, Frank MG, Licht T, Reshef R, Ben-Menachem-Zidon O, Baratta MV, Maier SF, Yirmiya R. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry. 2014;19(6):699\u2013709.","journal-title":"Mol Psychiatry"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-023-01047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13041-023-01047-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-023-01047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T12:05:27Z","timestamp":1689163527000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/s13041-023-01047-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1047"],"URL":"https:\/\/doi.org\/10.1186\/s13041-023-01047-5","relation":{},"ISSN":["1756-6606"],"issn-type":[{"value":"1756-6606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"31 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures and experiments were performed by the Institute for Protein Research, Osaka University animal committee regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no conflict of interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}